However, the glioma, especially GBM, still remains incurable with poor prognosis, which imposes enormous pressure on society, although some clinically relevant epigenetic biomarkers such as IDH status, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, histone code, and chromatin organization have been used for classification of glioma and treatment decisions (9). The gene discussed is MGMT; the disease is glioblastoma.